Follow the company. Check the evidence.
Public records connected to stocks traded by Congress. See what changed, when it became public, and the original source.
AMGN: Department of Health and Human Services contract award
NPLATE ADMINISTRATION KIT DEVELOPMENT FOR THE TREATMENT OF APPROVED INDICATIONS, INCLUDING ACUTE RADIATION SYNDROME (ARS)
2 congressional households disclosed purchases in the past 90 days. See the trades
AMGN: 10-Q financial filing
Filed 10-Q for an event or period dated 2026-09-30. Read the company report for its disclosures.
2 congressional households disclosed purchases in the past 90 days. See the trades
AMGN: Financial results
Filed 8-K for an event or period dated 2026-11-03. Financial results.
2 congressional households disclosed purchases in the past 90 days. See the trades
AMGN: Leadership change
Filed 8-K for an event or period dated 2026-10-26. Leadership change.
2 congressional households disclosed purchases in the past 90 days. See the trades
AMGN: third_quarter 2026 lobbying report
Monitor healthcare regulations and statutes and educate members of Congress on issues with regard to client's interests
Public: Oct 22, 2026, 2:29 PM EDTOriginal source ↗2 congressional households disclosed purchases in the past 90 days. See the trades
AMGN: third_quarter 2026 lobbying report
Issues related to drug pricing Issues related to cardiovascular disease awareness and treatment Issues related to reimbursement for biologics/biosimilars Issues related to PBM reform Issues related to bone disease awareness and treatment S.3345, PBM Price Transparency and Accountability Act HR 6166, Lowering Drug Costs for American Families Act S 3019 - No Big Blockbuster Bailouts Act S 3349 PBM Disclosure Act HR 4317 PBM Reform Act Issues related to Public law 117-1769 Inflation Reduction Act HR 1672 Maintaining Investments in New Innovation Act (MINI) HR 4299 Protecting Patient Access to Can
Public: Oct 20, 2026, 4:03 PM EDTOriginal source ↗2 congressional households disclosed purchases in the past 90 days. See the trades
AMGN: third_quarter 2026 lobbying report
Issues related to drug pricing and reimbursement for prescription drugs; Issues related to H.R. 4299, Protecting Patient Access to Cancer and Complex Therapies Act; Issues related to H.R. 5526/S. 1954, Biosimilar Red Tape Elimination Act; Issues related to Senate Finance Dear Colleague process; H.R. 10628/S. 5571, Biosimilars Access and Affordability Act
Public: Oct 20, 2026, 3:38 PM EDTOriginal source ↗2 congressional households disclosed purchases in the past 90 days. See the trades
AMGN: third_quarter 2026 lobbying report
Lobbying related to pharmaceutical policy and health care access Lobbying related to pharmaceutical policy and Medicare policy federal budget issues
Public: Oct 20, 2026, 1:27 PM EDTOriginal source ↗2 congressional households disclosed purchases in the past 90 days. See the trades
AMGN: third_quarter 2026 lobbying report
Provide advice and strategic counsel with regard to matters that could impact biopharmaceutical manufacturers generally and Amgen specifically, including Medicare Part D, Medicare Part B, Health Care Reform, Medicaid, FDA regulatory issues, and corporate tax reform.
Public: Oct 20, 2026, 12:35 PM EDTOriginal source ↗2 congressional households disclosed purchases in the past 90 days. See the trades
AMGN: third_quarter 2026 lobbying report
Medicare Part D and Medicare Part B drug reimbursement, policies around MFN drug pricing, Pharmacy benefit manager reform proposals. H.R. 1, "One Big Beautiful Bill Act" implementation, coverage and access for biosimilars. Tax issues related to the pharmaceutical industry. Implementation of PL 119-21. Policies impacting disease prevention. Issues related to antitrust legislation. Issues related to patent protections. General education about federal policies impacting pharmaceutical development, approval, and patient access. 340B, Policies impacting public health preparedness and prevention. Po
Public: Oct 20, 2026, 12:02 PM EDTOriginal source ↗2 congressional households disclosed purchases in the past 90 days. See the trades
AMGN: third_quarter 2026 lobbying report
Healthcare policy issues as they relate to the pharmaceutical industry including drug pricing and biosimilars Issues related to drug pricing, biosimilars, Medicare Part D and Medicare Part B; H.R. 3517 - Increasing Access to Osteoporosis Testing for Medicare Beneficiaries Act of 2021 Issues related to visas
Public: Oct 20, 2026, 11:29 AM EDTOriginal source ↗2 congressional households disclosed purchases in the past 90 days. See the trades
AMGN: third_quarter 2026 lobbying report
Issues related to the implementation of the Medicare Drug Negotiations and the calculation of the Medicaid Rebate and Best Price. issues relating to MFN pricing and other price controls in drugs.
Public: Oct 19, 2026, 11:23 PM EDTOriginal source ↗2 congressional households disclosed purchases in the past 90 days. See the trades
AMGN: third_quarter 2026 lobbying report
Issues related to Medicare and Medicaid drug pricing; Issues related to biosimilar access and affordability; Issues related to H.R. 10628/S.5571 - Biosimilars Access and Affordability Act. Issues related to the 340B Program - Public Health Service Act (PL 78-410); Issues related to H.R. 5526/S. 1954 - Biosimilar Red Tape Elimination Act.
Public: Oct 19, 2026, 5:53 PM EDTOriginal source ↗2 congressional households disclosed purchases in the past 90 days. See the trades
AMGN: third_quarter 2026 lobbying report
Medicare Part B coverage and reimbursement issues; Medicare Part D coverage issues. AI in health care. 340B Program issues.
Public: Oct 19, 2026, 5:48 PM EDTOriginal source ↗2 congressional households disclosed purchases in the past 90 days. See the trades
AMGN: third_quarter 2026 lobbying report
HR 10628, Biosimilars Access and Affordability
Public: Oct 19, 2026, 5:18 PM EDTOriginal source ↗2 congressional households disclosed purchases in the past 90 days. See the trades
AMGN: third_quarter 2026 lobbying report
PBM reform. Cardiovascular disease awareness and treatment. Bone disease awareness and treatment. Implementation of Inflation Reduction Act. Public Law No. 119-21, formerly H.R.1,One Big Beautiful Bill Act (OBBBA). Drug pricing and patient affordability. Issues related to 340B. Biosimilars reimbursement and regulatory standards. Issues related to Supply Chain. H.R.1672: Maintaining Investments in New Innovation (MINI) Act. Appropriations. S.2: Secure America Act (Reconciliation 2.0). H.R.8800: National Defense Authorization Act for Fiscal year 2027. H.R.3160/S.1553: Promoting and Respecting Ec
Public: Oct 19, 2026, 1:05 PM EDTOriginal source ↗2 congressional households disclosed purchases in the past 90 days. See the trades
AMGN: third_quarter 2026 lobbying report
issues related to pharmaceutical drugs
Public: Oct 18, 2026, 6:10 PM EDTOriginal source ↗2 congressional households disclosed purchases in the past 90 days. See the trades
AMGN: third_quarter 2026 lobbying report
Issues related to the pharmaceutical industry.
Public: Oct 13, 2026, 9:00 AM EDTOriginal source ↗2 congressional households disclosed purchases in the past 90 days. See the trades
AMGN: second_quarter 2026 lobbying report
Issues related to the implementation of the Medicare Drug Negotiations and the calculation of the Medicaid Rebate and Best Price. issues relating to MFN pricing and other price controls in drugs.
Public: Jul 21, 2026, 4:35 PM EDTOriginal source ↗2 congressional households disclosed purchases in the past 90 days. See the trades
AMGN: second_quarter 2026 lobbying report
Medicare/Medicaid payment reform. Implementation of Inflation Reduction Act of 2022. Prescription Drug Pricing Policy. Supply Chain Issues. Prescription drug pricing policy.
Public: Jul 20, 2026, 6:12 PM EDTOriginal source ↗2 congressional households disclosed purchases in the past 90 days. See the trades
AMGN: second_quarter 2026 lobbying report
Issues related to drug pricing Issues related to cardiovascular disease awareness and treatment Issues related to FDA Issues related to patient affordability issues, including copay cards, copay accumulators, copay maximizers, National Benefit Payment Parameters Issues related to biosimilars reimbursement Issues related to Supply Chain Issues related to 340B Issues related to pharmacy benefit managers Issues related to biosimilars regulatory standards Issues related to bone disease awareness and treatment Issues related to Public law 117-1769 Inflation Reduction Act HR 1492 Ensuring Pathways t
Public: Jul 20, 2026, 4:02 PM EDTOriginal source ↗2 congressional households disclosed purchases in the past 90 days. See the trades
AMGN: second_quarter 2026 lobbying report
Issues related to drug pricing and reimbursement for prescription drugs; Issues related to H.R. 4299, Protecting Patient Access to Cancer and Complex Therapies Act; Issues related to H.R. 5526/S. 1954, Biosimilar Red Tape Elimination Act; Issues related To S. 5459, The Biosimilar Access and Affordability Act; Issues related to Senate Finance Dear Colleague process
Public: Jul 20, 2026, 1:55 PM EDTOriginal source ↗2 congressional households disclosed purchases in the past 90 days. See the trades
AMGN: second_quarter 2026 lobbying report
Policies impacting disease prevention. Issues related to antitrust legislation. Issues related to patent protections. General education about federal policies impacting pharmaceutical development, approval, and patient access. 340B, Policies impacting public health preparedness and prevention. Policies impacting Cardiovascular and bone health. Pharmacy benefit manager reform proposals. FDA reform, prescription drug reimportation and new proposals. Medicare Part D and Medicare Part B drug reimbursement, policies around MFN drug pricing, Pharmacy benefit manager reform proposals. H.R. 1, "One Bi
Public: Jul 20, 2026, 1:55 PM EDTOriginal source ↗2 congressional households disclosed purchases in the past 90 days. See the trades
AMGN: second_quarter 2026 lobbying report
issues related to pharmaceutical drugs
Public: Jul 20, 2026, 1:43 PM EDTOriginal source ↗2 congressional households disclosed purchases in the past 90 days. See the trades
AMGN: second_quarter 2026 lobbying report
Provide advice and strategic counsel with regard to matters that could impact biopharmaceutical manufacturers generally and Amgen specifically, including Medicare Part D, Medicare Part B, Health Care Reform, Medicaid, FDA regulatory issues, and corporate tax reform.
Public: Jul 20, 2026, 11:30 AM EDTOriginal source ↗2 congressional households disclosed purchases in the past 90 days. See the trades
Connections describe public records, not evidence of wrongdoing or a prediction of returns. Event dates can precede publication by days or months. When a source has no public-release timestamp, we show when we first observed it.
Source coverage
Coverage is growing across companies already tracked here. A scan can return no matching records. This feed is not a complete record of every filing or agency action.
- SEC EDGAR
- Partial coverage — some requests unavailable455 of 455 companies scanned in the past 12 hoursLatest successful company scan: Nov 8, 2026, 11:36 PM EST
- USAspending
- Partial coverage — some requests unavailable284 of 495 companies scanned in the past 12 hoursLatest successful company scan: Nov 8, 2026, 11:38 PM EST
- SAM.gov
- Not connected
- Lobbying disclosures
- Partial coverage — some requests unavailable75 of 495 companies scanned in the past 12 hoursLatest successful company scan: Nov 8, 2026, 11:29 PM EST
- Congress.gov
- Current across tracked companies2 of 2 companies scanned in the past 12 hoursLatest successful company scan: Nov 8, 2026, 11:17 PM EST
- Federal Register
- Partial coverage — some requests unavailable384 of 495 companies scanned in the past 12 hoursLatest successful company scan: Nov 8, 2026, 11:38 PM EST
- Regulations.gov
- Partial coverage — some requests unavailable23 of 51 companies scanned in the past 12 hoursLatest successful company scan: Nov 8, 2026, 11:38 PM EST
- FEC campaign finance
- Stale — refresh overdue264 of 495 companies scanned in the past 12 hoursLatest successful company scan: Nov 8, 2026, 11:38 PM EST